JP7438975B2 - Cxcr3リガンド - Google Patents

Cxcr3リガンド Download PDF

Info

Publication number
JP7438975B2
JP7438975B2 JP2020559959A JP2020559959A JP7438975B2 JP 7438975 B2 JP7438975 B2 JP 7438975B2 JP 2020559959 A JP2020559959 A JP 2020559959A JP 2020559959 A JP2020559959 A JP 2020559959A JP 7438975 B2 JP7438975 B2 JP 7438975B2
Authority
JP
Japan
Prior art keywords
cxcr3
cxcr3 ligand
g1t4k
g1t4h
vhn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020559959A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020116498A5 (cg-RX-API-DMAC7.html
JPWO2020116498A1 (ja
Inventor
陽平 山本
実香 櫻井
健太 原谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of JPWO2020116498A1 publication Critical patent/JPWO2020116498A1/ja
Publication of JPWO2020116498A5 publication Critical patent/JPWO2020116498A5/ja
Application granted granted Critical
Publication of JP7438975B2 publication Critical patent/JP7438975B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020559959A 2018-12-04 2019-12-04 Cxcr3リガンド Active JP7438975B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018227353 2018-12-04
JP2018227353 2018-12-04
PCT/JP2019/047382 WO2020116498A1 (ja) 2018-12-04 2019-12-04 Cxcr3リガンド

Publications (3)

Publication Number Publication Date
JPWO2020116498A1 JPWO2020116498A1 (ja) 2021-10-14
JPWO2020116498A5 JPWO2020116498A5 (cg-RX-API-DMAC7.html) 2022-12-07
JP7438975B2 true JP7438975B2 (ja) 2024-02-27

Family

ID=70974705

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020559959A Active JP7438975B2 (ja) 2018-12-04 2019-12-04 Cxcr3リガンド

Country Status (4)

Country Link
US (2) US12624077B2 (cg-RX-API-DMAC7.html)
EP (1) EP3892330A4 (cg-RX-API-DMAC7.html)
JP (1) JP7438975B2 (cg-RX-API-DMAC7.html)
WO (1) WO2020116498A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3892330A4 (en) 2018-12-04 2022-10-26 Chugai Seiyaku Kabushiki Kaisha CXCR3 LIGAND
CA3194929A1 (en) * 2020-06-21 2021-12-30 Technion Research & Development Foundation Limited Modified cxcl10 for immunotherapy of cancer diseases
US20230242606A1 (en) * 2020-06-21 2023-08-03 Technion Research & Development Foundation Limited Cxcl9 and variants thereof for immunotherapy of cancer diseases
WO2023120643A1 (ja) 2021-12-23 2023-06-29 中外製薬株式会社 Cxcr3発現細胞遊走活性が増強したcxcr3リガンド。
CN121338000B (zh) * 2025-11-13 2026-08-04 中山大学 Rab30-dt抑制剂在制备预防和治疗肿瘤的药物中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082335A1 (fr) 2002-04-03 2003-10-09 Sumitomo Pharmaceuticals Co., Ltd. Nouveau dispositif de controle du sucre dans le sang et procede de criblage associe
JP2007525188A (ja) 2003-05-16 2007-09-06 インターミューン インコーポレイテッド 合成ケモカイン受容体リガンドおよびその使用方法
WO2018097308A1 (ja) 2016-11-28 2018-05-31 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028474A2 (en) 1997-12-01 1999-06-10 The Government Of The United States Of America, Represented By The Secretary Of Health And Human Services Chemokine variants and methods of use
AU2903999A (en) * 1998-03-12 1999-09-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
US7091310B2 (en) * 2002-09-13 2006-08-15 Chemokine Therapeutics Corporation Chemokine analogs for the treatment of human disease
US20090131312A1 (en) 2005-05-18 2009-05-21 Lawrence Blatt Non-natural chemokine receptor ligands and methods of use thereof
US7696309B2 (en) 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
WO2012172336A2 (en) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating inflammatory skin diseases
EP3096777B1 (en) 2014-01-21 2021-01-20 University of Pittsburgh - Of the Commonwealth System of Higher Education Goblet cell replacement therapy
EP3892330A4 (en) 2018-12-04 2022-10-26 Chugai Seiyaku Kabushiki Kaisha CXCR3 LIGAND
WO2021038033A1 (en) 2019-08-29 2021-03-04 Antagonis Biotherapeutics Gmbh T-cell mobilizing cxcl10 mutant with increased glycosaminoglycan binding affinity
WO2023120643A1 (ja) 2021-12-23 2023-06-29 中外製薬株式会社 Cxcr3発現細胞遊走活性が増強したcxcr3リガンド。

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082335A1 (fr) 2002-04-03 2003-10-09 Sumitomo Pharmaceuticals Co., Ltd. Nouveau dispositif de controle du sucre dans le sang et procede de criblage associe
JP2007525188A (ja) 2003-05-16 2007-09-06 インターミューン インコーポレイテッド 合成ケモカイン受容体リガンドおよびその使用方法
WO2018097308A1 (ja) 2016-11-28 2018-05-31 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子

Also Published As

Publication number Publication date
EP3892330A4 (en) 2022-10-26
US12624077B2 (en) 2026-05-12
US20260217779A1 (en) 2026-07-30
US20220017585A1 (en) 2022-01-20
WO2020116498A1 (ja) 2020-06-11
JPWO2020116498A1 (ja) 2021-10-14
EP3892330A1 (en) 2021-10-13

Similar Documents

Publication Publication Date Title
US12006361B2 (en) Albumin binding domain fusion proteins
US12624077B2 (en) CXCR3 ligand
CN113474367A (zh) 结合cd3和hla-a*02限制性肽的半衰期延长的immtac
CN108602871A (zh) 用于治疗自身免疫疾病的选择性地活化调节性t细胞的分子
CN105518025A (zh) 人抗IFN-α抗体
US20240376172A1 (en) Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
JP5581214B2 (ja) 改善された結合活性をもつ可溶性gp130変異蛋白質
US20250073307A1 (en) Cxcr3 ligand having enhanced cxcr3-expressing cell migration activity
US20020052475A1 (en) High affinity soluble interleukin-18 receptor
CN121194988A (zh) 白细胞介素-2变体及其应用
AU2019305086B2 (en) Soluble polypeptides and methods of using same for inhibiting leukemia inhibitory factor activity
HK40108361A (en) Cxcr3 ligand having enhanced cxcr3-expressing cell migration activity
RU2854870C2 (ru) Агонисты il-15 для лечения рака
EP4719458A2 (en) Il10 inverted monomers
EP4562059A1 (en) Il-15 agonists for cancer
HK40126456A (en) Albumin binding domain fusion proteins
HK40015886B (en) Albumin binding domain fusion proteins
HK40015886A (en) Albumin binding domain fusion proteins
EP3325515B1 (en) Novel binding proteins based on di-ubiquitin muteins and methods for generation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240214

R150 Certificate of patent or registration of utility model

Ref document number: 7438975

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150